Guanethidine was administered to 10 normal subjects in order to examine the effects of reduced adrenergic function on plasma volume. An increase in the plasma volume was observed averaging 21.4% after 1 week, and 12.1% and 13.1% after 2 and 3 weeks of drug administration. A similar change in plasma volume resulted when alphaadrenergic blockade was produced with phenoxybenzamine. These changes occurred in the absence of sodium retention and were associated with attenuation of forearm venous sympathetic reflexes and a rise in forearm venous compliance. The increase in venous compliance which was observed was proportional to the changes in plasma volume in these subjects. Thus, the sympathetic nervous system through its control of venous resistance may provide a means whereby the blood volume can be regulated.
IN ADDITION to its well recognized effects on the heart and blood vessels, the adrenergic nervous system may be an important determinant of the total blood volume and thereby may provide an additional mechanism wherein it may influence cardiovascular function. This concept has been suggested by observations indicating that administration of epinephrine or norepinephrine reduces plasma volume acutely,' 2 This work was supported by Grants HE-09932 and HE-05722 from the National Heart Institute, U. S. Public Health Service, and from the Colorado Heart Association. Dr. Weil was supported by Research Fellowship HE-33,642 from the U. S. Public Health Service. 54 Phenoxybenzamine in hypertensive patients treated with guanethidine,4, 5it is recognized that this drug can produce congestive heart failure in patients with underlying heart disease.6 Indeed, the reported plasma volume changes in hypertensive patients occurred in association with sodium retention and diminished glomerular filtration. Thus, previously it has not been possible to determine whether there is a direct effect of diminished sympathetic function on the blood volume. In contrast to its effects on patients with cardiovascular disease, guanethidine does not produce sodium retention, diminished glomerular filtration, or congestive heart failure in normal man.7 8 Time (Weeks) Figure 1 The effect of guanethidine on plasma volume in nine normal, nonhospitalized subjects. The average values are plotted with their standard errors. volume, determined by the 51Cr method, rose from 34.9 ± 0.9 ml/kg to 38.8 + 1.2 ml/kg (P < 0.01). The T 1824 plasma volumes in this group by comparison averaged 38.5 + 1.4 ml/ kg and 42.1 + 1.5 ml/kg (P < 0.05), respectively, during the control and treatment periods. Thus, the increments in plasma volume in these subjects were almost identical by the two methods, 3.9 + 1.0 ( 5'Cr) and 3.6 ± 2.3 (T 1824). These results support the validity of the T 1824 method under these circumstances and suggest that the observed plasma volume increases were not due to an alteration of the F-cells factor or other artifact introduced by the administration of guanethidine.
The effect of guanethidine administration on the excretion of catecholamines and their major metabolite, vanilmandelic acid, was studied in 10 patients (fig. 2) venomotor constriction in the control state manifest as an 11.0% decrease in basal venous compliance while this response was 3.5% during guanethidine and 2.1% during phenoxybenzamine (P < 0.01 forearm volume in the control state in these subjects. This basal level of venous compliance was less consistently changed by drug administration. In the guanethidine group, the changes in basal venous compliance were variable and on the average a significant increase was not observed, whereas in the phenoxybenzamine group, the mean venous compliance was increased, 0.49 + 0.11 ml/ 100 ml (P <0.05). When the changes in venous compliance in all eight of the subjects were considered in relation to the degree of augmentation of plasma volume, it appeared that a correlation between these two variables was present ( fig. 4) . The coefficient of regression between the change in plasma volume and the change in venous compliance was significant, r = + 0.755 (P < 0.025). One of the eight subjects had no change in plasma volume and a rather large reduction in venous compliance. These findings suggest that drug administration did not significantly alter vascular tone in this subject. Administration of guanethidine and phenoxybenzamine in these eight subjects did not result in a consistent change in the sodium balance during the drug period. The mean cumulative sodium balance in these subjects during the 1 week of drug administration was -5 mEq with guanethidine and +7 mEq with phenoxybenzamine; these values Control Guanethidine ranged from -58 to +65 mEq. Body weight remained essentially constant during the balance studies, falling only slightly during guanethidine, 0.55 kg, and rising slightly during phenoxybenzamine, 0.83 kg. The sodium balance data from the subject in whom the largest plasma volume increase occurred are shown in conjunction with serial observations of venous compliance and large vessel hematocrit ( fig. 5) tone and venomotor reflexes do not provide direct information regarding the venular resistance or capillary pressure, they do demonstrate effective interference with sympathetic innervation of the venous circulation by the administered drugs. It is presumed that similar alterations in the venular resistance vessels also occurred and that these were responsible for the increase in plasma volume observed with inhibition of sympathetic function. Thus, the present findings suggest that adrenergic activity may contribute to the control of cardiovascular function through its effects on total blood volume, as well as through its established effects on the circulation. This relationship between adrenergic activity and blood volume may serve to buffer the changes in cardiac filling pressure which occur in the presence of altered distensibility of the capacitance vasculature.
